Pulmonary edema and congestive heart failure (both referred to here as PE) have been reported to be complications of bilateral renal artery stenosis or unilateral stenosis in a solitary functioning kidney (both referred to as BRAS). The goals of this study were to determine whether a history of PE was more common in patients with BRAS than in those with unilateral stenosis and a normal contralateral kidney (URAS), and whether recurrent PE could be prevented by renal artery stent placement.
R ecurrent pulmonary edema has been shown to be associated with functionally significant bilateral renal artery stenosis or unilateral renal artery stenosis with an absent or intrinsically impaired contralateral kidney (both referred to here as BRAS). 1 Recently, congestive heart failure has also been reported to be a consequence of renovascular disease. 2 Patients with renovascular disease clearly have many possible explanations for developing pulmonary edema or congestive heart failure. These include concomitant atherosclerotic coronary artery disease and diastolic dysfunction from hypertensive cardiomyopathy. 3 However, several case reports and two recently published series of patients have shown that, in patients with BRAS, recurrent pulmonary edema and congestive heart failure (both referred to here as PE) can be prevented by successful surgical revascularization or percutaneous angioplasty of one or both renal arteries. [1] [2] [3] [4] [5] [6] [7] Thus, PE in patients with BRAS may be secondary to the resulting decreased renal blood flow and increased sodium retention. 4 Patients with bilateral renovascular disease and pulmonary edema or congestive heart failure have few therapeutic options. Medical therapy, especially with angiotensin converting enzyme inhibitors, may further impair renal perfusion, leading to increased azotemia. 8 Surgical renal artery revascularization has been shown to provide durable resolution of pulmonary edema 1, 3, 4, 7 ; however, these patients frequently have severe comorbid medical conditions, leading to increased surgical risk. Percutaneous transluminal renal artery angioplasty has also been shown to decrease recurrence of pulmonary edema, 1 but has a substantial restenosis rate, especially for ostial lesions. 9 Recently, percutaneous renal artery stent placement has been shown to be superior to routine angioplasty in the treatment of atheromatous lesions, the majority of which are usually present at the ostium. 10 At least one report has shown that a small number of patients with congestive heart failure have benefited from stent placement. 2 As such, stent placement may provide increased durability over routine angioplasty in the prevention of recurrent PE without the increased morbidity of surgical revascularization.
We examined the records of 90 consecutive patients with atheromatous renovascular disease who underwent renal artery stent placement in one or both renal arteries at our institution. The principal goals of this retrospective observational study were to determine whether a history of pulmonary edema or congestive heart failure was more common in subjects with bilateral renal artery stenosis or its anatomical correlates (BRAS) than in subjects with unilateral stenosis and a normal contralateral kidney (URAS); and whether recurrent PE was prevented by renal artery stent placement. Additionally, we assessed whether subjects with BRAS and a previous history of PE had other clinical characteristics that differentiated them from the subjects with BRAS and no history of PE.
MATERIALS AND METHODS
Between April of 1992 and July of 1997, 90 patients with atheromatous (nontransplant) renal artery disease underwent percutaneous renal artery stent placement at our institution. Patients underwent baseline arteriography followed by placement of a stainless steel nonarticulated Palmaz stent (Johnson & Johnson Interventional Systems Co., Warren, NJ) at the site of the stenosis. Selective angiography was performed after stent implantation to insure proper deployment.
The clinical indications for this procedure were renovascular hypertension with or without suspected ischemic nephropathy. Any renal artery lesion that resulted in a greater than 75% diameter stenosis as measured by angiography or a mean arterial gradient of Ն 20 mm Hg was considered hemodynamically significant. Only lesions that fulfilled this definition were considered for intervention. In keeping with our usual protocol, hemodynamically significant ostial lesions were routinely stented after angioplasty. In addition, any nonostial hemodynamically significant lesion that had an unsatisfactory angiographic response to routine balloon angioplasty was stented. In patients with bilateral hemodynamically significant disease, the decision to intervene on one or both renal arteries was at the discretion of the attending radiologist and the referring physician. Only patients who underwent actual deployment of a stent were included in this analysis.
The medical records of all 90 patients were reviewed. Before undergoing the procedure, the following information was obtained: history of pulmonary edema or congestive heart failure; demographics (age and gender); history of diabetes mellitus, smoking, atherosclerotic heart disease, peripheral vascular disease; most recent blood pressure readings; most recent serum creatinine; number of antihypertensive medications; and estimation of left ventricular (LV) function, as assessed by echocardiography or cardiac catheterization, when available. Often only qualitative information on LV function was available (ie, normal, mild, or severe dysfunction, etc); when exact estimation of LV function was provided, an ejection fraction (EF) Ն 50% was considered indicative of normal or mildly decreased LV function, and an EF Ͻ 50% was considered indicative of moderate to severe LV dysfunction. Renal insufficiency was defined as a baseline creatinine Ն133 mmol/L (Ն1.5 mg/dL).
Episodes of pulmonary edema or congestive heart failure were defined as a visit to the emergency room or admission to the hospital with such a diagnosis made by the treating physician. After stent placement, follow-up information was obtained by review of clinic and hospital charts and phone contact with the patients and their referring physicians. Follow-up information consisted of most recent blood pressure, most recent serum creatinine, number of antihypertensive medications, and number and date of any recurrent episodes of pulmonary edema or congestive heart failure (as defined earlier).
The renovascular anatomy was determined at the time of angiography by the attending radiologist. The presence of unilateral or bilateral disease was deter-mined using the previous definition for hemodynamic significance. Subsequently, patients with a history of pulmonary edema or congestive heart failure were divided into two groups. The first group, BRAS-PE, consisted of those patients with either hemodynamically significant bilateral renal artery stenosis or unilateral renal artery stenosis with an absent or poorly functioning contralateral kidney (defined as an estimated split renal function Ͻ 20% of total on nuclear renography or a total length Յ 7 cm on ultrasound or other imaging modality). The second group, URAS-PE, consisted of patients with unilateral hemodynamically significant renal artery stenosis and a normally functioning contralateral kidney. The rate of pulmonary edema recurrence after stent placement was calculated in each group.
The prevalences of pre-stent PE were compared in the BRAS and URAS groups using Fisher's two-tailed exact test and 2 analysis. Using the pre-stent variables, patients with BRAS-PE were compared with patients who had anatomy consistent with BRAS but no history of PE and with those with URAS. This analysis was performed using an unpaired t test for continuous variables and 2 analysis for noncontinuous variables. Patients with BRAS-PE who had no recurrence of PE after stent placement were compared with the BRAS-PE patients with recurrence using the same statistical analysis. Additionally, in those patients with BRAS-PE and successfully ameliorated pulmonary edema, pre-stent and late follow-up variables were compared using a paired t test.
RESULTS
The 90 patients who underwent renal artery stent placement included 56 with hemodynamically significant bilateral renal artery stenosis or its anatomical correlates (BRAS) and 34 with unilateral renal artery stenosis and a normal contralateral kidney (URAS). Of the 56 patients with bilateral stenosis, 11 (20%) had bilateral stent placement and 45 (80%) had unilateral stent placement.
There were 27 subjects in the entire cohort with a documented history of one or more episodes of PE before stent placement. A history of PE was significantly more prevalent in the subjects with BRAS than in those with URAS, as shown in Figure 1 .
There were 23 patients with BRAS-PE, and their clinical characteristics are given in Table 1 . Estimation of LV function was available in 20 of the 23 (87%) patients with a history of BRAS-PE. Similar information was available in only 30% of the remainder of patients. Of those patients with BRAS-PE, 80% had normal or mildly decreased left ventricular function and 20% had moderate to severe left ventricular dysfunction.
For the 90 stent patients as a group, the mean duration of follow-up was 18.1 months, with a range of 1 to 57 months. Of the 27 subjects with a history of PE before stent placement, 25 had adequate post-stent clinical follow-up to be included in the following analysis (22 BRAS and three URAS). The mean duration of follow-up after revascularization for patients with a history of PE was 18.4 months, with a range of 2 to 52 months. Details of these 25 patients are presented in Table 2 . At last available follow-up, of the 22 BRAS-PE subjects with adequate clinical follow-up, 17 (77%) had no further episodes of PE after renal artery stent placement. Before revascularization, nine of the 17 cured patients had experienced at least three episodes of acute pulmonary edema requiring hospitalization or presentation to the emergency room. The remaining eight patients had at least one welldocumented episode of pulmonary edema or congestive heart failure before stent placement. In most of these cases the medical history was inadequate to determine whether there may have been more than one episode.
Five of the 22 subjects (23%) in the BRAS-PE group did experience recurrent PE after stent placement. One of these patients was an 86-year-old woman with intractable pulmonary edema who had experienced two cardiac arrests before revascularization. This patient had bilateral renal artery near-total occlusions, one of which was stented. After an initial brisk diuresis, the patient's renal function deteriorated, and urgent repeat angiography revealed an acute thrombosis within the stent, which did not respond well to intraarterial thrombolytics. This patient died within 30 days of the procedure after recurrent bouts of pulmonary edema. A second patient was a 92-year-old woman who had previously undergone unilateral nephrectomy. This patient presented with intractable congestive heart failure and had a poor clinical response to stent deployment across a severely stenotic renal artery lesion. Acute thrombosis within the stent was suspected, but the patient refused repeat angiography and went on to require hemodialysis to control renal function and congestive heart failure. The third and fourth patients in this group were both free of recurrent pulmonary edema for more than 18 months after revascularization; however, at follow-up angiography (performed at 4 and 24 months post-stenting, respectively) both patients were found to have significant restenosis, and both went on to develop late recurrence of congestive heart failure. The final patient in this group was free of recurrent PE for 12 months after stent placement, but then presented with increasing symptoms of congestive heart failure and deteriorating renal function. Angiography revealed significant restenosis within and distal to the stent. The stent and the distal lesion were redilated, and over the ensuing 48 h the patient experienced a 5-L diuresis and is now free of pulmonary complaints.
In contrast to the BRAS-PE subjects, of the three subjects in the URAS-PE group, only one (33%) was without recurrent PE after apparently successful revascularization. Unfortunately, the small number of patients in the URAS-PE group prevents a meaningful statistical comparison of the two groups.
At last available follow-up, the 17 patients in the BRAS-PE group who had long-term cure of pulmonary edema also had improvement in other clinical variables. There was a decrease in average systolic blood pressure from 185.5 mm Hg to 151.1 mm Hg (P Ͻ .001). Average diastolic blood pressure decreased from 87.6 mm Hg to 81.4 mm Hg (P ϭ .040). The average number of antihypertensive medications decreased from 3.94 to 2.76 (P ϭ .005). The average serum creatinine decreased from 234.3 mmol/L (2.65 mg/dL) to 192.7 mmol/L (2.18 mg/dL), although this change was not statistically significant (P ϭ .334). The five patients with BRAS-PE who had recurrence of PE did not have statistically significant improvement in these variables at last follow-up. A comparison of the pre-stent clinical variables among the following three groups is provided in Table  2 ; data are given for subjects with BRAS-PE, subjects with BRAS anatomy but no pre-stent history of PE, and subjects with URAS anatomy with or without PE. As compared with subjects with BRAS and no history of PE, those with BRAS-PE were taking a significantly higher number of antihypertensive medications and had a higher prevalence of renal insufficiency before stent placement. When comparing these two groups no other clinical variables were found to have statistically significant differences. When compared with the URAS group, subjects with BRAS-PE were taking a significantly higher number of blood pressure medications, had a higher baseline serum creatinine, 
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higher prevalence of renal insufficiency, and a lower prevalence of diabetes mellitus. Additionally, when the 17 cured BRAS-PE subjects were compared with the five BRAS-PE subjects who had recurrence of PE, there were no identifiable significant differences in prestent variables.
DISCUSSION
Our results confirm that subjects with bilateral renal artery stenosis or unilateral stenosis in a solitary functioning kidney had a high incidence of recurrent pulmonary edema and congestive heart failure when compared with patients with unilateral disease and a normal contralateral kidney. We also report that in patients with bilateral renal artery stenosis or its anatomic correlates and pulmonary edema or congestive heart failure long-term prevention of pulmonary symptoms can be accomplished through successful percutaneous placement of a stent in one or both renal arteries. In this study, 91% of these subjects had no further PE episodes for at least 1 year after revascularization, and 77% had no recurrence at long-term follow-up. The majority of these subjects had normal or at worst mildly decreased LV function. The data suggest that the hemodynamic derangement of renal artery stenosis is a contributing factor in the development of pulmonary edema and congestive heart failure in patients with BRAS. Each subject with BRAS-PE who had recurrent PE after stent placement had evidence of stent thrombosis or restenosis. Unfortunately, follow-up angiograms were not obtained in the majority of those patients who had satisfactory clinical outcomes. In subjects with unilateral stenosis and a normal contralateral kidney, stent placement did not seem to effectively control PE recurrence. The number of patients (n ϭ 3) in this group was too small to permit satisfactory statistical comparison with the BRAS-PE group, but it can be inferred that pulmonary edema and congestive heart failure in these patients was most likely due to a mechanism independent of renal artery stenosis.
These findings support the hypothesis that patients with renovascular disease who have their entire functional renal mass subject to ischemia have a propensity to develop pulmonary edema and congestive heart failure. Although few physiologic studies have been done in humans, pulmonary edema in these patients is most likely the result of volume overload due to decreased compensatory natriuresis, in accordance with the animal models of Goldblatt hypertension.
Other investigators have demonstrated a marked diuresis after successful surgical revascularization or percutaneous angioplasty in subjects with BRAS-PE. 5, 6, 11 This finding supports the contention that pulmonary edema was secondary to relative volume overload as a result of decreased pressure natriuresis. Although this hypothetical mechanism is likely correct given experimental data in dogs, 10, 12 further studies need to be undertaken to better characterize the physiology of bilateral renovascular disease in humans. Studies of renal blood flow, glomerular filtration rate, and filtration fraction in patients with suspected bilateral renovascular disease before and after renal revascularization are in progress.
All patients with renovascular disease do not necessarily benefit from revascularization. As clinicians become more aware of renovascular disease as a cause of chronic renal insufficiency more patients are being referred for angiography. Before revascularization, it is very difficult to determine which of these patients will receive benefits from either a surgical or percutaneous procedure. The patients in this cohort tended to be elderly with a large number of medical comorbidities, and were often critically ill. Patients such as these have a greater likelihood of suffering complications of surgical or percutaneous revascularization procedures than do younger, healthier patients with unilateral disease and intact overall renal function. As such, it is necessary to develop guidelines to determine which patients are more likely to benefit from these procedures.
In this study the majority of the BRAS-PE patients had a favorable clinical outcome after stent placement; thus patients with suspected renovascular disease and a history of pulmonary edema or congestive heart failure should be considered for angiography and stent placement. Unfortunately, pre-stent clinical criteria did not distinguish subjects with BRAS-PE who were cured from those who were not. However, compared with patients with BRAS and no history of PE, those with BRAS-PE were taking a greater number of antihypertensive medications and had a higher prevalence of azotemia, suggesting that they had more advanced disease.
Although this study did not compare stent placement with other means of surgical or percutaneous intervention, there is evidence that stent placement may provide more durable patency than routine angioplasty for atherosclerotic ostial lesions without the potential morbidities of surgical revascularization. 10 Clearly, randomized clinical trials are needed to determine the relative benefits of surgical revascularization, standard percutaneous angioplasty, and stent placement in patients with renovascular disease.
In this series of 90 consecutive patients who underwent renal artery stent placement, pulmonary edema and congestive heart failure were significantly more prevalent in patients with bilateral renal artery stenosis or its anatomical equivalents than in patients with unilateral disease. Also, the majority of patients with pulmonary edema or congestive heart failure associated with bilateral renovascular disease achieved durable prevention of recurrent pulmonary symptoms by percutaneous stent placement in one or both renal arteries. Although more work needs to be done to determine the overall prevalence of this association and its physiology, the presence of one or more episodes of pulmonary edema or congestive heart failure without an obvious cause in a hypertensive patient with some degree of renal insufficiency should warrant an evaluation for renovascular disease.
